参考文献/References:
[1] Fuller PM, Gooley JJ,Saper CB.Neurobiology of the sleep-wake cycle: sleep architecture, circadian regulation, and regulatory feedback[J].J Biol Rhythms,2006,21(6):482-493.
[2] Van Someren EJW.Brain mechanisms of insomnia: new perspectives on causes and consequences[J].Physiol Rev,2021,101(3):995-1046.
[3] Sateia MJ, Buysse DJ,Krystal AD,et al.Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American academy of sleep medicine clinical practice guideline[J].J Clin Sleep Med,2017,13(2):307-349.
[4] Sarathi Chakraborty D,Choudhury S,Lahiry S.Daridorexant, a recently approved dual orexin receptor antagonists (DORA) in treatment of insomnia[J].Sleep Sci,2023,16(2):256-264.
[5] Wu X, Xue T,Chen ZQ,et al.Orexin receptor antagonists and insomnia[J].Curr Psychiatry Rep,2022,24(10):509-521.
[6] Uchiyama M,Kambe D,Imadera Y,et al.Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study[J].Psychopharmacology (Berl),2022,239(7):2143-2154.
[7] Xia LB, Liu HY,Wang BY,et al.A review of physiological functions of orexin:from instinctive responses to subjective cognition[J].Medicine (Baltimore),2023,102(26):e34206.
[8] Harris GC, Aston-Jones G.Arousal and reward: a dichotomy in orexin function[J].Trends Neurosci,2006,29(10):571-577.
[9] Han Y, Yuan K,Zheng YB,et al.Orexin receptor antagonists as emerging treatments for psychiatric disorders[J].Neurosci Bull,2020,36(4):432-448.
[10] Hoyer D, Jacobson LH.Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?[J].Neuropeptides,2013,47(6):477-488.
[11] Trivedi P, Yu H,MacNeil DJ,et al.Distribution of orexin receptor mRNA in the rat brain[J].FEBS Lett,1998,438(1/2):71-75.
[12] ASCHKENASI CJ,LEE CE.Differential expression of orexin receptors 1 and 2 in the rat brain[J].J Comp Neurol,2001,435(1):6-25.
[13] 任栓成,胡志安.丘脑网状核-丘脑室旁核通路在睡眠/觉醒调控中的作用[C]//中国睡眠研究会.中国睡眠研究会第十二届全国学术年会论文汇编.2020.
[14] Pantazis CB,James MH,OConnor S,et al.Orexin-1 receptor signaling in ventral tegmental area mediates cue-driven demand for cocaine[J].Neuropsychopharmacology,2022,47(3):741-751.
[15] Liblau RS, Vassalli A,Seifinejad A,et al.Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy[J].Lancet Neurol,2015,14(3):318-328.
[16] Lee MG, Hassani OK,Jones BE.Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle[J].J Neurosci,2005,25(28):6716-6720.
[17] Adamantidis AR,Zhang F,Aravanis AM,et al.Neural substrates of awakening probed with optogenetic control of hypocretin neurons[J].Nature,2007,450(7168):420-424.
[18] Saper CB, Scammell TE,Lu J.Hypothalamic regulation of sleep and circadian rhythms[J].Nature,2005,437(7063):1257-1263.
[19] Wang CM, Wang QQ,Ji BY,et al.The orexin/receptor system: molecular mechanism and therapeutic potential for neurological diseases[J].Front Mol Neurosci,2018,11:220.
[20] Salomon RM,Ripley B,Kennedy JS,et al.Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects[J].Biol Psychiatry,2003,54(2):96-104.
[21] Mogavero MP, Godos J,Grosso G,et al.Rethinking the role of orexin in the regulation of REM sleep and appetite[J].Nutrients,2023,15(17):3679.
[22] Chemelli RM, Willie JT,Sinton CM,et al.Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation[J].Cell,1999,98(4):437-451.
[23] Willie JT, Chemelli RM,Sinton CM,et al.Distinct narcolepsy syndromes in orexin receptor-2 and orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes[J].Neuron,2003,38(5):715-730.
[24] Peyron C, Faraco J,Rogers W,et al.A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains[J].Nat Med,2000,6(9):991-997.
[25] Ten-Blanco M, Flores ,Cristino L,et al.Targeting the orexin/hypocretin system for the treatment of neuropsychiatric and neurodegenerative diseases:from animal to clinical studies[J].Front Neuroendocrinol,2023,69:101066.
[26] Barson JR, Leibowitz SF.Orexin/hypocretin system: role in food and drug overconsumption[J].Int Rev Neurobiol,2017,136:199-237.
[27] Marcus JN, Aschkenasi CJ,Lee CE,et al.Differential expression of orexin receptors 1 and 2 in the rat brain[J].J Comp Neurol,2001,435(1):6-25.
[28] Callander GE.Suvorexant for the treatment of insomnia[J].Expert Rev Clin Pharmacol,2014,7(6):711-730.
[29] Michelson D,Snyder E,Paradis E,et al.Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial[J].Lancet Neurol,2014,13(5):461-471.
[30] Herring WJ,Connor KM,Ivgy-May N,et al.Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials[J].Biol Psychiatry,2016,79(2):136-148.
[31] Citrome L.Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?[J].Int J Clin Pract,2014,68(12):1429-1441.
[32] Herring WJ, Connor KM,Snyder E,et al.Suvorexant in elderly patients with insomnia: pooled analyses of data from phase III randomized controlled clinical trials[J].Am J Geriatr Psychiatry,2017,25(7):791-802.
[33] Patel KV, Aspesi AV,Evoy KE.Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia[J].Ann Pharmacother,2015,49(4):477-483.
[34] Schutte-Rodin S,Broch L,Buysse D,et al.Clinical guideline for the evaluation and management of chronic insomnia in adults[J].J Clin Sleep Med,2008,4(5):487-504.
[35] Yardley J,Krpp M,Inoue Y,et al.Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial[J].Sleep Med,2021,80:333-342.
[36] Dayal S, Aluri J,Hall N,et al.Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant[J].Pharmacol Res Perspect,2021,9(2):e00758.
[37] Landry I, Aluri J,Hall N,et al.Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant[J].Pharmacol Res Perspect,2021,9(2):e00734.
[38] Jiang FY, Li H,Chen YT,et al.Daridorexant for the treatment of insomnia disorder:a systematic review and meta-analysis of randomized controlled trials[J].Medicine (Baltimore),2023,102(7):e32754.
[39] Riemann D, Espie CA,Altena E,et al.The European insomnia guideline: an update on the diagnosis and treatment of insomnia 2023[J].J Sleep Res,2023,32(6):e14035.
[40] Phillips-Beyer A,Kawata AK,Kleinman L,et al.Meaningful Within-Patient change on the insomnia daytime symptoms and impacts questionnaire (IDSIQ): analysis of phase III clinical trial data of daridorexant[J].Pharmaceut Med,2023,37(4):291-303.
[41] Kunz D, Dauvilliers Y,Benes H,et al.Long-term safety and tolerability of daridorexant in patients with insomnia disorder[J].CNS Drugs,2023,37(1):93-106.
[42] Williams SG,Rodriguez-Cué D.Use of daridorexant among patients with chronic insomnia: a retrospective observational analysis[J].J Clin Med,2023,12(9):3240.
[43] 王淑娟,陶利军,王福乐.食欲素系统在睡眠障碍影响认知功能的研究进展[J].现代预防医学,2019,46(15):2834-2836, 2869.
[44] 朱敏侠.食欲素调节心血管活动的研究进展[J].基础医学与临床,2023,43(5):822-826.
[45] 刘传勇.双重食欲素受体拮抗剂suvorexant对阿尔茨海默病潜在防治作用的研究进展[J].慢性病学杂志,2023,24(4):526-529, 534.
[46] Firouzabadi N,Navabzadeh N,Moghimi-Sarani E,et al.Orexin/hypocretin type 2 receptor (HCRTR2) gene as a candidate gene in sertraline-associated insomnia in depressed patients[J].Neuropsychiatr Dis Treat,2020,16:1121-1128.
[47] 陈艳,李华,安晓,等.食欲素改善大鼠抑郁样行为及其受体机制研究[J].中国药业,2020,29(13):18-20.